|
Delayed
OTC Markets
01:01:41 2026-09-18 pm EDT
|
5-day change | 1st Jan Change | ||
| 0.0180 USD | -21.74% |
|
+1.55% | -11.54% |
| May. 18 | Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Nov. 17 | Adaptimmune Therapeutics plc Announces CEO Changes | CI |
| Market Cap | 6.1M 5.32M 5.02M 4.56M 8.54M 585M 8.58M 60.13M 23.2M 297M 22.9M 22.39M 957M | P/E 2024 |
-1.8x | P/E 2025 | 0.33x |
|---|---|---|---|---|---|
| Enterprise Value | -5.77M -5.03M -4.75M -4.32M -8.09M -554M -8.12M -56.94M -21.97M -282M -21.69M -21.2M -906M | EV / Sales 2024 |
0.34x | EV / Sales 2025 | -0.84x |
| Free-Float |
14.03% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 week | +1.55% | ||
| Current month | +2.22% | ||
| 1 month | -10.51% | ||
| 3 months | -42.50% | ||
| 6 months | +27.78% | ||
| Current year | -11.54% |
| 1 week | 0.01 |  | 0.03 |
| 1 month | 0 | | 0.03 |
| Current year | 0 | | 0.05 |
| 1 year | 0 | | 0.28 |
| 3 years | 0 | | 2.05 |
| 5 years | 0 | | 5.95 |
| 10 years | 0 | | 14.62 |
| Manager | Title | Age | Since |
|---|---|---|---|
Christopher Hill
CEO | Chief Executive Officer | 46 | 2025-11-13 |
Juli P. Miller
IRC | Investor Relations Contact | - | 2016-07-31 |
Phil Bassett
PRN | Corporate Officer/Principal | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Lawrence Alleva
CHM | Chairman | 76 | 2025-11-13 |
Garry Menzel
BRD | Director/Board Member | 61 | 2023-05-31 |
Christopher Hill
BRD | Director/Board Member | 46 | 2025-11-13 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/2/25 | Sell | Chief Financial Officer | 96,000 | 0.0060% | ||
| 8/28/25 | Sell | Compliance Officer | 207,000 | 0.0130% | ||
| 8/15/25 | NEA Management Co. LLC
| Sell | Company | 19,500,000 | 7.3571% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -21.74% | +1.55% | -85.62% | -96.89% | 6.1M | |
| -0.59% | +0.39% | +31.04% | -4.84% | 78.83B | |
| -1.11% | +3.59% | -12.67% | -34.40% | 60.48B | |
| -1.58% | +7.98% | +510.84% | +49.28% | 63.11B | |
| +0.14% | -1.76% | -10.86% | +24.38% | 46.75B | |
| -0.24% | +1.22% | +2.26% | +151.03% | 45.66B | |
| -0.78% | -0.13% | +50.80% | -14.39% | 32.37B | |
| -0.28% | +4.69% | +47.87% | +113.69% | 25.87B | |
| +0.47% | +2.38% | +0.10% | +146.43% | 21.33B | |
| +0.27% | +1.96% | +62.19% | +102.81% | 15.8B | |
| Average | -0.38% | +2.99% | +59.59% | +43.71% | 39.02B | |
| Weighted average by Cap. | -0.61% | +3.94% | +95.80% | +40.77% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 178M 155M 147M 133M 249M 17.08B 250M 1.76B 678M 8.69B 669M 654M 27.95B | 5.92M 5.17M 4.88M 4.43M 8.3M 568M 8.33M 58.43M 22.55M 289M 22.25M 21.76M 930M |
| Net income | -70.81M -61.75M -58.31M -52.95M -99.2M -6.79B -99.61M -698M -270M -3.45B -266M -260M -11.12B | 25.21M 21.98M 20.75M 18.85M 35.31M 2.42B 35.46M 249M 95.93M 1.23B 94.69M 92.58M 3.96B |
| Net Debt | -77.4M -67.49M -63.73M -57.87M -108M -7.43B -109M -763M -295M -3.78B -291M -284M -12.15B | -11.87M -10.35M -9.77M -8.87M -16.63M -1.14B -16.7M -117M -45.17M -579M -44.59M -43.6M -1.86B |
Employees
272
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-18 | $0.0180 | -21.74% | 43,726 |
| 26-09-17 | $0.0230 | -8.00% | 69,921 |
| 26-09-16 | $0.0250 | 0.00% | 242,213 |
| 26-09-15 | $0.0250 | +4.17% | 228,690 |
| 26-09-14 | $0.0240 | +5.96% | 187,980 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ADAPY Stock
Select your edition
All financial news and data tailored to specific country editions
